由于业务的改善、债务的减少和现金流动的加强,分析员将Teva升级。 Analysts upgrade Teva due to improved operations, debt reduction, and stronger cash flow.

美国证券银行升级了Teva制药公司,以便购买,并提高了价格目标,理由是业务改进、减债和结构调整取得进展。 Bank of America Securities upgraded Teva Pharmaceutical to Buy and raised its price target, citing improved operations, debt reduction, and progress in restructuring. 摩根大通和瑞银也提高了目标, 指出现金流,资产剥离以及特种仿制药和生物仿制药的潜力更强. JPMorgan and UBS also raised their targets, noting stronger cash flow, asset divestitures, and potential in specialty generics and biosimilars. 虽然价格压力和法律风险依然存在,但分析家们看到,随着制药部门向业务效率和输油管力量转变,对Teva的长期复苏和创造价值的信心日益增强。 While pricing pressures and legal risks persist, analysts see growing confidence in Teva’s long-term recovery and value creation amid a shift toward operational efficiency and pipeline strength in the pharmaceutical sector.